1. Background/Objective {#sec1}
=======================

Chemotherapy-induced nausea and vomiting (CINV) negatively impacts the quality of life in cancer patients \[[@B1]\] and may lead to nonadherence to or dose reductions in chemotherapy \[[@B2]\]. Potential cardiac effects of antiemetics warrant special attention, given an estimated 13--60% burden of cardiovascular-related diseases that increases with age, among cancer patients \[[@B3]--[@B5]\]. Cardiovascular disease (CVD) can be preexisting, a result or natural progression of the malignancy or an adverse event resulting from chemotherapeutic treatment, such as anthracyclines and alkylating agents \[[@B6], [@B7]\]. For example, cyclophosphamide treatment has been associated with a 7--28% incidence of heart failure, cisplatin has been associated with an 8.5% incidence of venous thromboembolism, including deep vein thrombosis and pulmonary embolism \[[@B8]\], and doxorubicin/daunorubicin has been associated with 0.5--3% incidence of arrhythmias \[[@B9]\].

Aprepitant is currently the only FDA-approved neurokinin (NK1) receptor antagonist (RA) that, when coadministered with other antiemetics, such as corticosteroids (dexamethasone) and serotonin 5-HT~3~ receptor antagonists (e.g., dolasetron, granisetron, ondansetron, and palonosetron), augments the prevention of acute and, particularly, delayed CINV \[[@B10]\]. Although aprepitant has been shown to be generally well tolerated in clinical trials \[[@B11]\], isolated cases of serious adverse events, such as bradycardia \[[@B12]\] and hypertension \[[@B13]\], have been reported in two highly emetogenic chemotherapy (HEC) studies comparing aprepitant plus ondansetron and dexamethasone to the standard regimen of ondansetron and dexamethasone, alone \[[@B14], [@B15]\]. Other cardiovascular events (\>0.5% and greater than standard therapy), regardless of causality, have also been reported in patients treated with the aprepitant regimen in either HEC or MEC studies, including myocardial infarction, tachycardia, deep vein thrombosis, flushing, hypertension, and hypotension \[[@B12]\]. However, results from clinical trials may not reflect those observed in clinical practice, and population-based studies of the cardiovascular effects of aprepitant are lacking. We aimed to quantify background rates of several CVD-related events among HEC and/or MEC-treated cancer patients for two purposes: to understand expected rates among cancer patients in order to contextualize events which may be seen in our clinical development program of a similar patient population with a similar drug and to further understand at a high level whether rates differed by the decision to treat with aprepitant, recognizing that users versus nonusers may differ with respect to disease severity, access to care, preexisting conditions, and other factors. Therefore, the objective of this study was to use a large, US healthcare claims database to assess the frequency of CVD-related events among HEC and/or MEC-treated cancer patients and to determine if the frequency was impacted by the decision to treat with aprepitant.

2. Methods {#sec2}
==========

A retrospective cohort study of adult patients with select cancers, treated with HEC and/or MEC, was conducted using 2005--2007 data from the IMPACT National Benchmark Database (OptumInsight, Eden Prairie, MN), a comprehensive, deidentified healthcare claims database that is representative of the nonelderly, insurance-carrying population in the United States. At the time of our analysis, the database contained inpatient/outpatient and pharmacy claims, a subset of lab results and enrolment information on over 82 million members from 45 healthcare plans serving nine census regions from 1997 to 2007. The IMPACT database is HIPAA compliant and features encrypted member and provider IDs.

The study included several cancer types commonly treated with HEC or MEC, namely, breast, colorectal, head and neck, lung, and ovarian cancer patients ([Table 4](#tab4){ref-type="table"}), in adults with ≤4 cycles of HEC and/or MEC as documented in one or more claims in the year 2006. We choose ≤4 cycles because two-thirds of all treated patients had up to and including 4 cycles. The study analysis period was defined as the first day of the first HEC and/or MEC cycle to 30 days past the first day of the last cycle. The start of a new cycle of chemotherapy was defined by a period of more than 7 days but less than 45 days between cycles. The start of treatment was the first HEC and/or MEC claim in 2006, with 3 months prior with no claim ("wash-in" period) to ensure that there was no CVD effect of HEC/MEC treatment in 2005 that was carried over into 2006. The end of treatment was reached after 45 days of no additional HEC and/or MEC claim following the last claim ("wash-out" period) to ensure that all CVD effects from HEC/MEC treatment in 2006 were captured. To illustrate, for patients whose first HEC or MEC claim was between January 1, 2006 and March 31, 2006, the enrolment criteria for inclusion in the study extended as far back as October 1, 2005. For patients whose last claim in 2006 was seen after December 1, 2006, enrolment into 2007 to look for further treatment and the 45 day "wash-out" period was required.

Data on aprepitant exposure and chemotherapy was obtained from the inpatient/outpatient and pharmacy claims. Chemotherapeutic agents were defined as HEC if they were associated with \>90% of treated patients having emesis, and MEC, if associated with 30--90% of patients having emesis ([Table 5](#tab5){ref-type="table"}). Chemotherapies were classified by a physician within our department using previously published criteria as guidance \[[@B16], [@B17]\]. Cardiovascular outcomes of interest included arterial and venous thromboembolic events, individually as well as a composite event, as well as cardiac arrest, hypertension, hypotension, increased platelets, sudden death, and syncope ([Table 4](#tab4){ref-type="table"}). Patient characteristics included gender, age, tumor type, and prior history of cardiovascular disease. Prior CVD was defined as the presence of a claim for hypertension, diabetes, coronary artery disease, myocardial infarction, congestive heart failure, ischemic stroke, transient ischemic attack, deep vein thrombosis, or pulmonary embolism anytime before HEC or MEC initiation.

Subjects who used either HEC or MEC were categorized into 3 emetogenic chemotherapy groups: HEC-only, MEC-only, or HEC/MEC combined. All analyses, including the distribution (% or mean) of patient characteristics and the frequency of CVD outcomes of interest, were tabulated overall and stratified by aprepitant usage and emetogenic category of chemotherapy. Analyses were not further stratified by number of chemotherapy cycles, however, due to insufficient sample size. This study was purely descriptive, and therefore, no formal statistical comparison was made between aprepitant users and nonusers. Rather, the data was visually inspected for noteworthy absolute differences of ≥5% or relative differences of ≥1.5 times.

3. Results {#sec3}
==========

The number of cancer patients with the cancer types of interest who had at least 3 months of continuous enrolment and pharmacy benefit, at least one HEC or MEC claim, and ≤4 cycles of chemotherapy was 5827. Among these patients, the distribution of patients by cancer type was 60.4% with breast, 25.7% with lung, 7.0% with colorectal, 5.9% with head and neck, and 5.6% with ovarian cancer ([Table 1](#tab1){ref-type="table"}). Over 90% of patients had treatment by MEC-only, followed by 5.7% with HEC-only and 3.9% with both HEC and MEC. Females comprised the majority across chemotherapy groups (55% HEC-only; 80% MEC-only; 58% HEC/MEC combination), and this gender difference was greater among those who took aprepitant compared to those who did not. The mean age (\~55 years) was similar across the chemotherapy groups, as was the percentage aged 60 years or older. Those taking aprepitant, however, were 2 to 4.8 years younger, on average, and comprised fewer patients aged 60+ years compared to those who did not take aprepitant. In HEC-only patients, 32% of aprepitant users were 60+ compared to 39% of nonusers; in MEC-only patients, the percentages were 20% versus 38%, respectively; and in the HEC/MEC combination group, the percentages were 35% versus 36%, respectively. Using a more traditional cutpoint of age 65+ years, similar results were found with aprepitant users having a smaller proportion of older patients than nonusers. Over half of patients had a history of CVD *before* their chemotherapy treatment, with the HEC-only group having a higher burden (62%) compared to the MEC-only group (50%) and HEC/MEC combined group (56%). The proportion with a prior history of CVD was lower in aprepitant users compared to nonusers.

Overall, the frequencies of cardiovascular and thromboembolic-related events *following* any HEC or MEC treatment were mostly driven by the MEC-only treatment group, comprising 90% of patients ([Table 2](#tab2){ref-type="table"}). There were no sudden deaths. The frequencies of increased platelets, arterial disorder, arterial occlusive disease, cardiac disorder, cardiogenic shock, iliac artery embolism, intermittent claudication and peripheral ischemia were low (*n* ≤ 10) in this cohort.

Hypertension occurred in 16% of the MEC-only chemotherapy group and was slightly higher among the smaller HEC-only and HEC/MEC combination groups. Chest pain or discomfort occurred in 12% of the MEC-only patients, in 19% of HEC-only patients, and in 21% of combined HEC/MEC patients. All other single adverse CVD events occurred at a frequency less than 5%, including MI and cerebrovascular accident, with the exception of hypotension, which occurred in 5.3% of those treated with HEC/MEC combined. The composite measure for arterial thromboembolic events, excluding chest pain and discomfort, ranged from 4% among the MEC-only group to 7% in the HEC-only group. The composite of venous thromboembolic events was 12% for the HEC-only and the HEC/MEC combined groups and 7% for the MEC-only group.

Stratified by the decision to include aprepitant in the antiemetic regimen ([Table 3](#tab3){ref-type="table"}), the analysis demonstrated that in the MEC-only treated group, the composite of arterial thromboembolic events (without chest pain and discomfort), cardiac arrest, cardiorespsiratory arrest, cerebral ischemia, cerebrovascular accident, embolism, hypotension, and hypertension were more frequent (≥1.5 times or ≥5% absolute difference) among those who did not use aprepitant compared to those who did. Though based on small numbers (*n* ≤ 10), nonusers also had a higher rate of circulatory collapse (10 versus 3), increased platelet (6 versus 1), intermittent claudication (3 versus 1), and myocardial ischemia (9 versus 2). In all but two events (arterial disorder and arterial occlusive disorder) of the CVD-related categories among the MEC-only treated group, the frequency of CVD events was lower among aprepitant users versus nonusers.

For the HEC-only and the combined HEC/MEC chemotherapy groups, the numbers of individual cardiovascular-related events were generally too small (*n* ≤ 10) to make reliable comparisons across aprepitant status. However, where cells sizes were larger, HEC-only-treated patients who did not use aprepitant compared to users had a higher frequency of chest pain/discomfort as a diagnosis, a composite diagnosis of arterial thromboembolic events, excluding chest pain and discomfort, hypertension, and a composite measure of venous thromboembolic events. Though rare (*n* ≤ 10), additional events that were more frequent among nonusers compared to aprepitant users included angina pectoris (2 cases versus 1), embolism (5 versus 3), and hypotension (7 versus 4); in contrast, aprepitant users had a higher frequency of syncope (4 cases versus 8) than nonusers.

Among patients treated with both HEC and MEC, there was a higher frequency of chest pain and discomfort as a diagnosis and a composite diagnosis of arterial thromboembolic events, including chest pain, in nonusers of aprepitant compared to users. Users had a higher frequency of hypotension (6 cases versus 6), intermittent claudication (2 versus 1), and peripheral embolism (2 versus 2).

4. Discussion {#sec4}
=============

The proportion of patients with CVD events was low (≤5%) for many events across all chemotherapy groups, except for hypertension and the composite measures for arterial thromboembolic and venous thromboembolic events. This is in line with population-based data showing an annual incidence (per 1000 persons) of myocardial infarction of about 4 for men and 2 for women (Atherosclerosis Risk In Communities Surveillance data, 1987--2001), an annual incidence (per 1000 persons) of angina pectoris of 4 to over 8 among men ages 45--54 and 65+ years, respectively, and 0.9 to over 4 among women ages 45--54 and 65+ years, respectively (National Heart, Lung, and Blood Institute data, 2006), and a 33.6% prevalence of hypertension among US adults 20 years and older (National Health and Nutrition Examination Survey data, 2003--2006) \[[@B18]\].

CVD occurrences were slighter higher for those treated with HEC only or HEC/MEC combined than those treated with MEC-only. In addition, the HEC/MEC combined group experienced a slightly elevated frequency of hypotension compared to the HEC-only or MEC-only groups. It is noteworthy that sample sizes for the HEC-only and HEC/MEC combination groups are orders of magnitude smaller than the MEC-only group, and, thus, slightly higher percentages observed in these two groups may be due to sample variability.

Those who did not use aprepitant compared to those who did generally experienced higher frequencies of certain CVD-related events, namely, cardiac arrest, hypertension, hypotension, the composite of arterial thromboembolic events without chest pain/discomfort, and, in particular, cardio-respiratory arrest, cerebral ischemia, cerebrovascular accident, and embolism among the MEC-only treated group; arterial thromboembolic events with chest pain among the HEC/MEC combined chemotherapy groups; arterial thromboembolic events without chest pain, hypertension, and venous thromboembolic events in the HEC-only treated group. While there were some CVD-related events that occurred at a higher frequency among aprepitant users compared to nonusers, the absolute number of events was small, and most events were either similar across the two groups or higher in the nonaprepitant user group. In particular, in the MEC-only group, with its large numbers of users and nonusers, arterial disorder was higher among aprepitant users but the occurrence of all other events was either similar or lower among aprepitant users compared to nonusers. This may be explained by the fact that nonusers were more likely than users to be older and have a prior history of cardiovascular disease.

Aprepitant is a substrate and dose-dependent inhibitor and inducer of the cytochrome P4503A4 (CYP3A4) isoenzyme, and drugs metabolized by CYPA34 can have a potential drug interaction with aprepitant \[[@B19]\]. For example, cyclophosphamide is an anticancer agent that is metabolized to its active metabolites by CYPA34 \[[@B10]\] and is also associated with cardiac side effects such as acute heart failure, pericardial effusion, and arrhythmia \[[@B7]\]. Coadministration with aprepitant causes a decrease in plasma concentrations of the active metabolites of cyclophosphamide by 5% \[[@B20]\], a level which may not be clinically significant \[[@B10]\].

Some 5-HT~3~ RA antiemetics (e.g., dolasetron, granisetron and ondansetron) have been associated with reversible, clinically insignificant changes to electrocardiographic (ECG) parameters (i.e., PR, QTS, QT, and JT intervals) \[[@B21]\], and their coadministration could have a diluting or enhancing effect on the occurrence of cardiovascular events.

As with all administrative databases, the claims data collected were not designed for research purposes, and, thus, are limited in scope and lack detailed clinical information available in medical records, such as ECG readings and lab data on MI-induced elevations of troponin, and so forth. A claim may represent a condition to be ruled out rather than diagnosis of the condition, itself. Discharge diagnosis for the identification of cardiovascular and thromboembolic events can have several sources of error, including variation in coding procedures, coding errors, incomplete coding, lack of specificity in available codes, and error in clinical diagnosis \[[@B22]\]. Misclassification of outcomes could lead to biased results. Nevertheless, the usefulness of claims data for certain CVD events has been assessed by other investigators. For example, a validation study of claim codes from a commercial insurance claims database, similar to IMPACT, against the gold standard medical records, showed a positive predictive value of 88% for both myocardial infarction and ischemic stroke \[[@B23]\].

This was a high-level analysis performed to provide overall background rates in a population of cancer patients similar to those under study in our clinical development program. It was not designed to draw causal inferences in differences between users of aprepitant and nonusers. The decision whether to treat with aprepitant most likely depends on many factors, such as the ability to pay for medications, physician experience, emetogenic potential of the chemotherapeutic agent, drug-drug interactions, and whether treatment is for acute or delayed CINV \[[@B24], [@B25]\]. We did not attempt to unmask or correct for potential channeling bias, nor did we consider other possible confounding factors between the aprepitant user and nonuser groups, including drug severity and comorbidity. Our comparisons did not take into account possible confounding due to drug-drug interactions with specific cardiotoxic chemotherapeutic agents or other coadministered antiemetics. We did not account for chemotherapeutic drug dosages and did not have adequate sample size for assessing effects among individual cycles of chemotherapy. As a next step, we would have corrected for as many of these shortcomings as possible in a subsequent, more rigorous pharmacoepidemiology study had our clinical development program advanced.

Despite these limitations, this analysis provided a "real world" clinical practice baseline picture of the frequency of CVD-related events that occur during use of highly or moderately emetogenic chemotherapy, serving as a useful benchmark for safety signals identified during one of our clinical trial programs. Results should also serve for future supportive care studies. The preliminary information on experiences of the aprepitant antiemetic group compared to nonusers was helpful but should be interpreted cautiously.
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###### 

Characteristics of 5827 patients with select\* cancers and ≤4 cycles of HEC, MEC, or HEC/MEC combined, 2005--2007 IMPACT National Benchmark Database (OptumInsight, Eden Prairie, MN).

  Characteristic               HEC and/or MEC   HEC only   MEC only   HEC/MEC combined                                                           
  ---------------------------- ---------------- ---------- ---------- ------------------ ------- ------- ------- ------- ------- ------- ------- -------
  \% Male                      21.90            27.56      11.14      45.45              52.73   38.18   19.57   25.59   7.52    41.67   47.48   32.58
  \% Female                    78.10            72.44      88.86      54.55              47.27   61.82   80.43   74.41   92.48   58.33   52.52   67.42
  Mean age (yrs)               54.7             56.3       51.7       54.8               55.8    53.8    54.6    56.2    51.4    56.2    57.1    54.8
  \% Age ≥60                   32.52            38.22      21.69      35.15              38.79   31.52   32.23   38.29   20.10   35.53   35.97   34.83
  \% Age ≥65                   14.35            18.31      6.82       14.85              16.97   12.73   14.22   18.33   5.98    16.67   19.42   12.36
  \% Breast cancer             60.41            50.98      78.31      26.67              19.39   33.94   64.07   53.74   84.74   24.56   18.71   33.71
  \% Colorectal cancer         7.00             9.30       2.64       6.97               6.67    7.27    6.95    9.45    1.94    8.33    8.63    7.87
  \% Head and neck cancer      5.85             5.74       6.07       26.97              26.67   27.27   3.93    4.18    3.42    19.74   20.14   19.10
  \% Lung cancer               25.73            32.91      12.09      36.67              44.85   28.48   24.05   31.51   9.11    48.68   53.96   40.45
  \% Ovarian cancer            5.59             6.47       3.93       6.67               7.27    6.06    5.60    6.55    3.70    3.95    3.60    4.49
  \% Prior history of CVD^‡^   50.76            55.28      42.19      61.52              64.85   58.18   49.86   54.68   40.21   56.14   58.99   51.69

**\***Breast, colorectal, head and neck, lung, and ovarian cancers.

^‡^Prior history of CVD is defined as a diagnosis of any of the following prior to the start of HEC and/or MEC: hypertension, diabetes, coronary artery disease, myocardial infarction, congestive heart failure, stroke, transient ischemic attack, deep vein thrombosis (DVT), and pulmonary embolism (PE).

Note: percentage by type of cancer may add to \>100% due to patients having multiple cancer types.

###### 

Cardiovascular-related events in 5827 patients with select\* cancers and ≤4 cycles of HEC, MEC, or HEC/MEC combined, 2005--2007 IMPACT National Benchmark Database (OptumInsight, Eden Prairie, MN).

  Cardiovascular and thromboembolic events                    HEC and/or MEC   HEC only   MEC only   HEC plus MEC                      
  ----------------------------------------------------------- ---------------- ---------- ---------- -------------- ----- ------- ---- -------
  Angina pectoris                                             32               0.55       3          0.91           28    0.53    1    0.44
  Arterial disorder                                           9                0.15       2          0.61           7     0.13    0    ---
  Arterial occlusive disease                                  2                0.03       0          ---            2     0.04    0    ---
  Arterial thromboembolic (excluding chest pain/discomfort)   254              4.36       23         6.97           220   4.18    11   4.82
  Arterial thromboembolic (including chest pain/discomfort)   881              15.12      72         21.82          754   14.31   55   24.12
  Cardiac arrest                                              25               0.43       4          1.21           19    0.36    2    0.88
  Cardiac disorder                                            3                0.05       0          ---            3     0.06    0    ---
  Cardio-respiratory arrest                                   27               0.46       4          1.21           21    0.40    2    0.88
  Cardiogenic shock                                           1                0.02       0          ---            1     0.02    0    ---
  Cerebral ischemia                                           62               1.06       8          2.42           53    1.01    1    0.44
  Cerebrovascular accident                                    52               0.89       3          0.91           49    0.93    0    ---
  Chest pain or discomfort                                    719              12.34      62         18.79          610   11.58   47   20.61
  Circulatory collapse                                        14               0.24       1          0.30           13    0.25    0    ---
  Embolism                                                    97               1.66       8          2.42           83    1.58    6    2.63
  Hypertension                                                966              16.58      68         20.61          854   16.21   44   19.30
  Hypotension                                                 149              2.56       11         3.33           126   2.39    12   5.26
  Iliac artery embolism                                       2                0.03       1          0.30           1     0.02    0    ---
  Increased platelets                                         7                0.12       0          ---            7     0.13    0    ---
  Intermittent claudication                                   9                0.15       2          0.61           4     0.08    3    1.32
  Myocardial infarction                                       11               0.19       1          0.30           10    0.19    0    ---
  Myocardial ischemia                                         11               0.19       0          ---            11    0.21    0    ---
  Peripheral embolism                                         38               0.65       4          1.21           30    0.57    4    1.75
  Peripheral ischemia                                         ---              ---        0          ---            0     ---     0    ---
  Sudden death                                                ---              ---        0          ---            0     ---     0    ---
  Syncope                                                     140              2.40       12         3.64           117   2.22    11   4.82
  Venous thromboembolic                                       450              7.72       40         12.12          383   7.27    27   11.84

**\***Breast, colorectal, head and neck, lung, and ovarian cancers.

###### 

Cardiovascular-related events in 5827 patients with select\* cancers and ≤4 cycles of HEC, MEC, or HEC/MEC combined, by aprepitant status, 2005--2007 IMPACT National Benchmark Database (OptumInsight, Eden Prairie, MN).

  Cardiovascular and thromboembolic events                   HEC and/or MEC   HEC only   MEC only   HEC/MEC combined                                                                           
  ---------------------------------------------------------- ---------------- ---------- ---------- ------------------ ---- ------- ---- ------- ----- ------- ----- ------- ---- ------- ---- -------
  Angina pectoris                                            20               0.52       12         0.60               2    1.21    1    0.61    18    0.51    10    0.57    0    ---     1    1.12
  Arterial disorder                                          3                0.08       6          0.30               1    0.61    1    0.61    2     0.06    5     0.28    0    ---     0    ---
  Arterial occlusive disease                                 1                0.03       1          0.05               0    ---     0    ---     1     0.03    1     0.06    0    ---     0    ---
  Arterial thromboembolic (excludes chest pain/discomfort)   196              5.13       58         2.89               14   8.48    9    5.45    175   4.98    45    2.56    7    5.04    4    4.49
  Arterial thromboembolic (includes chest pain/discomfort)   611              16.01      270        13.43              40   24.24   32   19.39   534   15.20   220   12.53   37   26.62   18   20.22
  Cardiac arrest                                             22               0.58       3          0.15               2    1.21    2    1.21    18    0.51    1     0.06    2    1.44    0    ---
  Cardiac disorder                                           2                0.05       1          0.05               0    ---     0    ---     2     0.06    1     0.06    0    ---     0    ---
  Cardio-respiratory arrest                                  24               0.63       3          0.15               2    1.21    2    1.21    20    0.57    1     0.06    2    1.44    0    ---
  Cardiogenic shock                                          1                0.03       0          ---                0    ---     0    ---     1     0.03    0     ---     0    ---     0    ---
  Cerebral ischemia                                          50               1.31       12         0.60               4    2.42    4    2.42    45    1.28    8     0.46    1    0.72    0    ---
  Cerebrovascular accident                                   46               1.21       6          0.30               3    1.82    0    ---     43    1.22    6     0.34    0    ---     0    ---
  Chest pain or discomfort                                   488              12.78      231        11.49              36   21.82   26   15.76   420   11.96   190   10.82   32   23.02   15   16.85
  Circulatory collapse                                       11               0.29       3          0.15               1    0.61    0    ---     10    0.28    3     0.17    0    ---     0    ---
  Embolism                                                   77               2.02       20         1.00               5    3.03    3    1.82    68    1.94    15    0.85    4    2.88    2    2.25
  Hypertension                                               697              18.26      269        13.38              41   24.85   27   16.36   629   17.90   225   12.81   27   19.42   17   19.10
  Hypotension                                                117              3.07       32         1.59               7    4.24    4    2.42    104   2.96    22    1.25    6    4.32    6    6.74
  Iliac artery embolism                                      1                0.03       1          0.05               0    ---     1    0.61    1     0.03    0     ---     0    ---     0    ---
  Increased platelets                                        6                0.16       1          0.05               0    ---     0    ---     6     0.17    1     0.06    0    ---     0    ---
  Intermittent claudication                                  5                0.13       4          0.20               1    0.61    1    0.61    3     0.09    1     0.06    1    0.72    2    2.25
  Myocardial infarction                                      11               0.29       0          ---                1    0.61    0    ---     10    0.28    0     ---     0    ---     0    ---
  Myocardial ischemia                                        9                0.24       2          0.10               0    ---     0    ---     9     0.26    2     0.11    0    ---     0    ---
  Peripheral embolism                                        25               0.65       13         0.65               2    1.21    2    1.21    21    0.60    9     0.51    2    1.44    2    2.25
  Peripheral ischemia                                        0                ---        0          ---                0    ---     0    ---     0     ---     0     ---     0    ---     0    ---
  Sudden death                                               0                ---        0          ---                0    ---     0    ---     0     ---     0     ---     0    ---     0    ---
  Syncope                                                    96               2.52       44         2.19               4    2.42    8    4.85    86    2.45    31    1.77    6    4.32    5    5.62
  Venous thromboembolic                                      308              8.07       142        7.06               24   14.55   16   9.70    268   7.63    115   6.55    16   11.51   11   12.36

**\***Breast, colorectal, head and neck, lung, and ovarian cancers.

###### 

ICD-9 codes for selected cancers and cardiovascular-related events.

  Cancer                           ICD-9-CM code(s)
  -------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  Breast                           174.0-174.6, 174.8, 174.9, 175, 175.0, 175.9
  Colorectal                       153, 153.0-153.9, 154, 154.0-154.3, 154.8, 230.3-230.6
  Head and neck                    140.0-140.9, 141.0-141.9, 142.0-142.9, 143.0-143.9, 144.0-144.9, 145.0-145.9, 146.0-146.9, 147.0-147.9, 148.0-148.9, 149.0-149.9, 161.0-161.9
  Lung                             162.2-162.5, 162.8, 162.9
  Ovarian                          183.0
                                   
  CVD-related events               ICD-9-CM code(s)
                                   
  Arterial Thromboembolic events   
   Angina pectoris                 413.x
   Arterial disorder               459.9
   Arterial occlusive disease      362.34
   Cardiac disorder                997.1
   Cardio-respiratory arrest       427.5, 799.1
   Cardiogenic shock               785.51
   Cerebral ischemia               435, 435.8, 435.9, 437.1
   Cerebrovascular accident        436, 437
   Chest pain or discomfort        586.5x
   Circulatory collapse            785.5, 785.50
   Embolism                        433, 434.x, 444.0--444.2, 444.21, 444.22, 444.81, 444.89, 444.9, 445, 445.01, 445.02, 445.81, 445.89
   Iliac artery embolism           444.81
   Intermittent claudication       440.21
   Myocardial infarction           410.x
   Myocardial ischemia             414.8
   Peripheral embolism             444.x
   Peripheral ischemia             414
  Cardiac Arrest                   427.5
  Hypertension                     401.x, 405.x, 401.0, 401.1, 401.9, 796.2
  Hypotension                      458.x
  Increased platelets              238.71, 287.1
  Sudden death                     798, 798.2
  Syncope                          780.0, 780.2, 780.9
  Venous thromboembolic events     
   Deep vein thrombosis            451.1, 451.11, 451.19, 451.2, 451.81, 451.83, 451.84, 453.1--453.4, 453.41, 453.42, 453.8, 453.9
   Phlebitis                       451.x
   Phlebitis superficial           451.1
   Pulmonary embolism              415.1, 415.11, 415.12, 415.19
   Superior vena cava occlusion    459.2, 901.2, 38.8
   Thrombophlebitis                451.x4
   Thrombophlebitis superficial    451.0, 451.82, 671.2x
   Varicophlebitis                 454.1, 454.2, 454.8
   Vena cava thrombosis            453.2
   Venous thrombosis               453.0, 453.4, 453.9

###### 

Chemotherapeutic agents according to HEC or MEC status.

  HEC or MEC    Chemotherapeutic agent                                        Strength        NDC or J-code
  ------------- ------------------------------------------------------------- --------------- ---------------
  Oral                                                                                        
                                                                                              
  MEC (low)     Arsenic                                                       10 MG/10 ML     60553011110
  MEC (low)     Arsenic                                                       10 MG/10 ML     63459060010
  MEC (low)     Carboplatin                                                   50 MG/0 ML      15321030
  MEC (low)     Carboplatin                                                   150 MG/10 ML    15321130
  MEC (low)     Carboplatin                                                   450 MG/40 ML    15321230
  MEC (low)     Carboplatin                                                   50 MG           15321330
  MEC (low)     Carboplatin                                                   150 MG          15321430
  MEC (low)     Carboplatin                                                   450 MG          15321530
  MEC (low)     Carboplatin                                                   10 MG/ML        591333712
  MEC (low)     Carboplatin                                                   10 MG/ML        591333889
  MEC (low)     Carboplatin                                                   10 MG/ML        703324411
  MEC (low)     Carboplatin                                                   10 MG/ML        703324611
  MEC (low)     Carboplatin                                                   10 MG/ML        703324811
  MEC (low)     Carboplatin                                                   10 MG/ML        703324911
  MEC (low)     Carboplatin                                                   50 MG           703326401
  MEC (low)     Carboplatin                                                   150 MG          703326601
  MEC (low)     Carboplatin                                                   450 MG          703326801
  MEC (low)     Carboplatin                                                   10 MG/ML        703424401
  MEC (low)     Carboplatin                                                   10 MG/ML        703424601
  MEC (low)     Carboplatin                                                   10 MG/ML        703424801
  MEC (low)     Carboplatin                                                   10 MG/ML        10019091202
  MEC (low)     Carboplatin                                                   10 MG/ML        10019091203
  MEC (low)     Carboplatin                                                   50 MG           10019091501
  MEC (low)     Carboplatin                                                   150 MG          10019091601
  MEC (low)     Carboplatin                                                   450 MG          10019091701
  MEC (low)     Carboplatin                                                   50 MG           50111096576
  MEC (low)     Carboplatin                                                   150 MG          50111096676
  MEC (low)     Carboplatin                                                   450 MG          50111096776
  MEC (low)     Carboplatin                                                   50 MG           55390015001
  MEC (low)     Carboplatin                                                   150 MG          55390015101
  MEC (low)     Carboplatin                                                   450 MG          55390015201
  MEC (low)     Carboplatin                                                   10 MG/ML        55390015301
  MEC (low)     Carboplatin                                                   10 MG/ML        55390015401
  MEC (low)     Carboplatin                                                   10 MG/ML        55390015501
  MEC (low)     Carboplatin                                                   10 MG/ML        61703033918
  MEC (low)     Carboplatin                                                   10 MG/ML        61703033922
  MEC (low)     Carboplatin                                                   10 MG/ML        61703033950
  MEC (low)     Carboplatin                                                   10 MG/ML        61703033956
  MEC (low)     Carboplatin                                                   150 MG          63323016721
  MEC (low)     Carboplatin                                                   450 MG          63323016800
  MEC (low)     Carboplatin                                                   10 MG/ML        63323016905
  MEC (low)     Carboplatin                                                   10 MG/ML        63323016915
  MEC (low)     Carboplatin                                                   10 MG/ML        63323016945
  MEC (low)     Carboplatin                                                   10 MG/ML        63323017245
  MEC (low)     Cyclophosphamide                                              100 MG          13560693
  MEC (low)     Cyclophosphamide                                              200 MG          13561693
  MEC (low)     Cyclophosphamide                                              500 MG          13562693
  MEC (low)     Cyclophosphamide                                              500 MG          15050241
  MEC (low)     Cyclophosphamide                                              50 MG           15050301
  MEC (low)     Cyclophosphamide                                              50 MG           15050302
  MEC (low)     Cyclophosphamide                                              25 MG           15050401
  MEC (low)     Cyclophosphamide                                              100 MG          15053941
  MEC (low)     Cyclophosphamide                                              200 MG          15054641
  MEC (low)     Cyclophosphamide                                              500 MG          15054741
  MEC (low)     Cyclophosphamide                                              25 MG           54412925
  MEC (low)     Cyclophosphamide                                              50 MG           54413025
  MEC (low)     Cyclophosphamide                                              25 MG           54808925
  MEC (low)     Cyclophosphamide                                              50 MG           54813025
  MEC (low)     Cyclophosphamide                                              500 MG          10019095501
  MEC (low)     Cytarabine                                                    1 GM            9329501
  MEC (low)     Cytarabine                                                    1 GM            703519401
  MEC (low)     Cytarabine                                                    1 GM            55390013301
  MEC (low)     Cytarabine                                                    1 GM            55390080801
  MEC (low)     Daunorubicin                                                  20 MG           703503203
  MEC (low)     Daunorubicin                                                  20 MG/4ML       55390010810
  MEC (low)     Daunorubicin                                                  20 MG           55390028110
  MEC (low)     Daunorubicin                                                  2 MG/ML         56146030101
  MEC (low)     Daunorubicin                                                  2 MG/ML         61958030101
  MEC (low)     Doxorubicin                                                   20 MG           13109691
  MEC (low)     Doxorubicin                                                   20 MG           13109694
  MEC (low)     Doxorubicin                                                   20 MG/10 ML     13114691
  MEC (low)     Doxorubicin                                                   20 MG/10 ML     13114694
  MEC (low)     Doxorubicin                                                   20 MG/10 ML     13124691
  MEC (low)     Doxorubicin                                                   50 MG/20 ML     13115679
  MEC (low)     Doxorubicin                                                   50 MG/20 ML     13125679
  MEC (low)     Doxorubicin                                                   50 MG           186153101
  MEC (low)     Doxorubicin                                                   50 MG           10019092102
  MEC (low)     Doxorubicin                                                   50 MG           55390023301
  MEC (low)     Doxorubicin                                                   50 MG           55390024301
  MEC (low)     Epirubicin                                                    2 MG/ML         9509101
  MEC (low)     Epirubicin                                                    2 MG/ML         9509301
  MEC (low)     Epirubicin                                                    50 MG           61703034735
  MEC (low)     Idarubicin                                                    5 MG            13250694
  MEC (low)     Idarubicin                                                    20 MG           13252686
  MEC (low)     Idarubicin                                                    1 MG/ML         13253678
  MEC (low)     Idarubicin                                                    1 MG/ML         13255667
  MEC (low)     Idarubicin                                                    1 MG/ML         13259691
  MEC (low)     Ifosfamide                                                    1 GM            15055605
  MEC (low)     Ifosfamide                                                    1 GM            15055611
  MEC (low)     Ifosfamide                                                    1 GM            15055641
  MEC (low)     Ifosfamide                                                    3 GM            15055741
  MEC (low)     Ifosfamide                                                    5 GM/3 GM       703410048
  MEC (low)     Ifosfamide                                                    1 GM            63323014210
  MEC (low)     Irinotecan                                                    20 MG/ML        9752901
  MEC (low)     Irinotecan                                                    20 MG/ML        9752902
  MEC (low)     Pentostatin                                                   10 MG           62701080001
  MEC (low)     Temozolomide                                                  5 MG            85124801
  MEC (low)     Temozolomide                                                  5 MG            85124802
  MEC (low)     Temozolomide                                                  5 MG            85124803
  MEC (low)     Temozolomide                                                  20 MG           85124401
  MEC (low)     Temozolomide                                                  20 MG           85124402
  MEC (low)     Temozolomide                                                  250 MG          85125201
  MEC (low)     Temozolomide                                                  250 MG          85125202
  MEC (low)     Temozolomide                                                  100 MG          85125901
  MEC (low)     Temozolomide                                                  100 MG          85125902
  MEC (low)     Temozolomide                                                  100 MG          85136601
  MEC (low)     Temozolomide                                                  100 MG          85136602
  MEC (low)     Temozolomide                                                  250 MG          85141701
  MEC (low)     Temozolomide                                                  140 MG          85142501
  MEC (low)     Temozolomide                                                  140 MG          85142502
  MEC (low)     Temozolomide                                                  180 MG          85143001
  MEC (low)     Temozolomide                                                  180 MG          85143002
  MEC (low)     Temozolomide                                                  20 MG           85151901
  MEC (low)     Temozolomide                                                  20 MG           85151902
  MEC (low)     Temozolomide                                                  20 MG           54868414205
  MEC (low)     Temozolomide                                                  20 MG           54868414206
  MEC (low)     Temozolomide                                                  5 MG            54868534801
  MEC (low)     Temozolomide                                                  100 MG          54868535002
  MEC (low)     Temozolomide                                                  250 MG          54868535400
  MEC (high)    Carmustine                                                    100 MG          15301238
  MEC (high)    Carmustine                                                    100 MG          15301297
  MEC (high)    Cisplatin                                                     50 MG/50 ML     15322022
  MEC (high)    Cisplatin                                                     50 MG/50 ML     15322097
  MEC (high)    Cisplatin                                                     1 MG/ML         703574711
  MEC (high)    Cisplatin                                                     1 MG/ML         703574811
  MEC (high)    Cisplatin                                                     1 MG/ML         10019091001
  MEC (high)    Cisplatin                                                     1 MG/ML         10019091002
  MEC (high)    Cisplatin                                                     50 MG/50 ML     55390011250
  MEC (high)    Cisplatin                                                     50 MG/50 ML     55390041450
  MEC (high)    Cisplatin                                                     1 MG/ML         63323010351
  MEC (high)    Cisplatin                                                     1 MG/ML         63323010364
  MEC (high)    Cisplatin                                                     1 MG/ML         63323010365
  MEC (high)    Cyclophosphamide                                              1 GM            13563670
  MEC (high)    Cyclophosphamide                                              1 GM            15050541
  MEC (high)    Cyclophosphamide                                              1 GM            15054812
  MEC (high)    Cyclophosphamide                                              1 GM            15054841
  MEC (high)    Cyclophosphamide                                              1 GM            10019095601
  MEC (high)    Cytarabine                                                    2GM             55390013401
  MEC (high)    Cytarabine                                                    2GM             55390080901
  MEC (high)    Cytarabine                                                    2000 MG/20 ML   61703031922
  MEC (high)    Cytarabine                                                    2000 MG/20 ML   61703031922
  MEC (high)    Dactinomycin                                                  0.5 MG          6329822
  MEC (high)    Dactinomycin                                                  0.5 MG          67386081155
  MEC (high)    Doxorubicin                                                   200 MG/100 ML   13116683
  MEC (high)    Doxorubicin                                                   75 MG/37.0 ML   13117687
  MEC (high)    Etoposide                                                     500 MG/20 ML    15306120
  MEC (high)    Etoposide                                                     1 GM/50 ML      15306220
  MEC (high)    Etoposide                                                     500 MG/20 ML    55390029201
  MEC (high)    Etoposide                                                     1000 MG/50 ML   55390029301
  MEC (high)    Etoposide                                                     500 MG/20 ML    55390049201
  MEC (high)    Etoposide                                                     1000 MG/50 ML   55390049301
  MEC (high)    Melphalan                                                     2 MG            81004535
  MEC (high)    Melphalan                                                     2 MG            173004535
  MEC (high)    Melphalan                                                     50 MG           173013093
  MEC (high)    Melphalan                                                     50 MG           173013093
  MEC (high)    Melphalan                                                     2 MG            54868433901
  MEC (high)    Melphalan                                                     2 MG            54868433902
  MEC (high)    Melphalan                                                     2 MG            59572030250
  MEC (high)    Methotrexate                                                  1 GM            55390014301
  MEC (high)    Methotrexate                                                  1000 MG/40 ML   63323012140
  MEC (high)    Methotrexate                                                  1 GM            63323012250
  MEC (high)    Methotrexate                                                  1 GM            66479013929
  MEC (high)    Procarbazine                                                  50 MG           4005301
  MEC (high)    Procarbazine                                                  50 MG           54482005301
  HEC           Cisplatin                                                     100 MG/100 ML   15322122
  HEC           Cisplatin                                                     100 MG/100 ML   55390011299
  HEC           Cyclophosphamide                                              2GM             13564670
  HEC           Cyclophosphamide                                              2GM             15050641
  HEC           Cyclophosphamide                                              2GM             15054941
  HEC           Cyclophosphamide                                              2GM             10019095701
  HEC           Dacarbazine                                                   200 MG          26815120
  HEC           Dacarbazine                                                   200 MG          703507501
  HEC           Dacarbazine                                                   200 MG          703507503
  HEC           Dacarbazine                                                   200 MG          55390009010
  HEC           Dacarbazine                                                   200 MG          61703032722
  HEC           Dacarbazine                                                   100 MG          63323012710
  HEC           Dacarbazine                                                   200 MG          63323012820
  HEC           Mechlorethamine                                               10 MG           6775331
  HEC           Mechlorethamine                                               10 MG           67386091151
  HEC           Streptozocin                                                  1 GM            9084401
  HEC           Streptozocin                                                  1 GM            703463601
                                                                                              
  Injectables                                                                                 
                                                                                              
  MEC (low)     Cyclophosphamide; oral                                        25 MG           J8530
  MEC (low)     Injection, arsenic trioxide                                   1 MG            J9017
  MEC (low)     Cyclophosphamide                                              100 MG          J9070
  MEC (low)     Cyclophosphamide                                              200 MG          J9080
  MEC (low)     Cyclophosphamide                                              500 MG          J9090
  MEC (low)     Cyclophosphamide, lyopholized                                 100 MG          J9093
  MEC (low)     Cyclophosphamide, lyopholized                                 200 MG          J9094
  MEC (low)     Cyclophosphamide, lyopholized                                 500 MG          J9095
  MEC (low)     Injection, epirubicin HCL                                     2 MG            J9178
  MEC (low)     Injection, irinotecan                                         20 MG           J9206
  MEC (low)     Injection, ifosfamide                                         1 GM            J9208
  MEC (low)     Injection, idarubicin hydrochloride                           5 MG            J9211
  MEC (low)     Injection, mitoxantrone hydrochloride                         Per 5 MG        J9293
  MEC (low)     Lomustine, oral                                               10 MG           S0178
  MEC (high)    Injection, carboplatin                                        50 MG           J9045
  MEC (high)    Injection, carmustine                                         100 MG          J9050
  MEC (high)    Cisplatin, powder or solution                                 PER 10 MG       J9060
  MEC (high)    Cyclophosphamide                                              1.0 GM          J9091
  MEC (high)    Cyclophosphamide, lyophilized                                 1.0 GM          J9096
  MEC (high)    Injection, dactinomycin                                       0.5 MG          J9120
  MEC (high)    Injection, melphalan hydrochloride                            50 MG           J9245
  MEC (high)    Pracarbazine hydrochloride, oral                              50 MG           S0182
  HEC           Cisplatin                                                     50 MG           J9062
  HEC           Cyclophosphamide                                              2.0 GM          J9092
  HEC           Cyclophosphamide, lyophilized                                 2.0 GM          J9097
  HEC           Dacarbazine                                                   100 MG          J9130
  HEC           Dacarbazine                                                   200 MG          J9140
  HEC           Injection, mechlorethamine hydrochloride (nitrogen mustard)   10 MG           J9230
  HEC           Injection, streptozocin                                       1 GM            J9320

MEC (low): moderately emetogenic chemotherapy associated with 30--60% of patients having emesis, MEC (high): moderately emetogenic chemotherapy associated with 60--90% of patients having emesis, HEC: highly emetogenic chemotherapy associated with \>90% of patients having emesis.

[^1]: Academic Editor: Jon Fryzek
